OmniAb, Inc.
Hsiang-Ting Ho is a Senior Scientist at OmniAb, Inc. since November 2022 and previously worked as a Senior Scientist at Icagen starting from August 2020. Before that, they held positions at Duke University Medical Center, including Senior Research Associate from September 2019 to August 2020 and Postdoctoral Fellow from April 2016 to August 2019. They also worked as a Post-Doctoral Researcher at The Ohio State University Wexner Medical Center from August 2013 to March 2016. Hsiang-Ting Ho's earlier experience includes being a Graduate Research Associate at the Department of Physiology and Cell Biology, The Ohio State University from June 2009 to August 2013, and a Graduate Research Associate at the Department of Chemical Engineering, The Ohio State University from September 2008 to March 2009. They also gained initial research experience as an Undergraduate Research Assistant at the Department of Biological Science and Technology, National Chiao Tung University from 2006 to 2008. Throughout their career, they have conducted research on various topics such as cardiac development, post-transcriptional modification, signal cascades, reactive oxygen species, and arrhythmogenicity. They have authored multiple publications in peer-reviewed journals and have presented at conferences.
Hsiang-Ting Ho has an extensive educational background in the field of biophysics. They obtained their Bachelor of Science degree in Electrophysics from National Chiao Tung University, graduating in 2008. Following this, they pursued further education at The Ohio State University, where they obtained a Master of Science degree in Biophysics, completing their studies in 2011. They continued their academic journey at The Ohio State University, culminating in the completion of a Ph.D. in Biophysics in 2013.
In addition to their formal education, Hsiang-Ting Ho also acquired a certification called "From the Laboratory to Leadership" from The Leadership Edge in November 2022.
This person is not in any offices
OmniAb, Inc.
The OmniAb discovery platform provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence (BI) of our proprietary transgenic animals, including OmniRat,OmniChicken and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur features unique structural attributes of cow antibodies for complex targets. OmniAb animals comprise the most diverse host systems available in the industry and they are optimally leveraged through computational antigen design and immunization methods, paired with high-throughput microfluidic-based single B cell screening and deep computational analysis of next-generation sequencing datasets to identify fully human antibodies with superior performance and developability characteristics. An established core competency focused on ion channels and transporters further differentiates our technology and creates opportunities to further leverage across modalities, including antibody-drug conjugates and others. The OmniAb suite of technologies and differentiating computational capabilities and BI features are combined to offer a highly efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry. For more information, please visit www.omniab.com.